Serological investigation of the clinical significance of fascin in non-small-cell lung cancer

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 346-352

  Teng, Yu ^a   Xu, Shaofa ^a   Yue, Wentao ^a   Ma, Li ^a   Zhang, Lina ^a   Zhao, Xiaoting ^a   Guo, Yinan ^a   Zhang, Chunyan ^a   Gu, Meng ^a   Wang, Yue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Fascin; Lung cancer; Metastatic; NSCLC; Prognosis

Indexed keywords

FASCIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FASCIN BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEROLOGY; TUMOR INVASION; TUMOR VOLUME;

FASCIN; LUNG CANCER; METASTATIC; NSCLC; PROGNOSIS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TUMOR BURDEN;

EID: 84887023093     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.017     Document Type: Article

References (37)

1. Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355:1763-1771.
2. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-831.
3. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-458.
4. Rosenthal D.T., Iyer H., Escudero S., Bao L., Wu Z., Ventura A.C., et al. Merajver SD. p38gamma promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res 2011, 71:6338-6349.
5. Pang H., Flinn R., Patsialou A., Wyckoff J., Roussos E.T., Wu H., et al. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res 2009, 69:8868-8876.
6. Zanet J., Jayo A., Plaza S., Millard T., Parsons M., Stramer B. Fascin promotes filopodia formation independent of its role in actin bundling. J Cell Biol 2012, 197:477-486.
7. Li A., Dawson J.C., Forero-Vargas M., Spence H.J., Yu X., Konig I., et al. The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion. Curr Biol 2010, 20:339-345.
8. Adams J.C. Characterization of cell-matrix adhesion requirements for the formation of fascin microspikes. Mol Biol Cell 1997, 8:2345-2363.
9. Zhang F.R., Tao L.H., Shen Z.Y., Lv Z., Xu L.Y., Li E.M. Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem 2008, 56:193-199.
10. De Arcangelis A., Georges-Labouesse E., Adams J.C. Expression of fascin-1, the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis. Gene Expr Patterns 2004, 4:637-643.
11. Alam H., Bhate A.V., Gangadaran P., Sawant S.S., Salot S., Sehgal L., et al. Fascin overexpression promotes neoplastic progression in oral squamous cell carcinoma. BMC Cancer 2012, 12:32.
12. McKnight R., Cohen C., Siddiqui M.T. Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation. Diagn Cytopathol 2011, 39:635-640.
13. Iguchi T., Aishima S., Umeda K., Sanefuji K., Fujita N., Sugimachi K., et al. Fascin expression in progression and prognosis of hepatocellular carcinoma. J Surg Oncol 2009, 100:575-579.
14. Choi P.J., Yang D.K., Son C.H., Lee K.E., Lee J.I., Roh M.S. Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3cm or less in diameter. Eur J Cardio Thorac Surg 2006, 30:538-542.
15. Pelosi G., Pastorino U., Pasini F., Maissoneuve P., Fraggetta F., Iannucci A., et al. Independent prognostic value of fascin immunoreactivity in stage I non-small cell lung cancer. Br J Cancer 2003, 88:537-547.
16. Pelosi G., Pasini F., Fraggetta F., Pastorino U., Iannucci A., Maisonneuve P., et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003, 42:203-213.
17. Roh Y.H., Kim Y.H., Choi H.J., Lee K.E., Roh M.S. Fascin overexpression correlates with positive thrombospondin-1 and syndecan-1 expressions and a more aggressive clinical course in patients with gallbladder cancer. J Hepatobiliary Pancreat Surg 2009, 16:315-321.
18. Yoder B.J., Tso E., Skacel M., Pettay J., Tarr S., Budd T., et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005, 11:186-192.
19. Rami-Porta R., Crowley J.J., Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009, 15:4-9.
20. Travis W.D., Brambilla E., Müller-Hermelink H.K., Harris C.C. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart 2004, 35-44. IARC Press, Lyon.
21. Tsai W.C., Chao Y.C., Sheu L.F., Chang J.L., Nieh S., Jin J.S. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2007, 23:153-160.
22. Tsai W.C., Jin J.S., Chang W.K., Chan D.C., Yeh M.K., Cherng S.C., et al. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J Histochem Cytochem 2007, 55:955-962.
23. Darnel A.D., Behmoaram E., Vollmer R.T., Corcos J., Bijian K., Sircar K., et al. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 2009, 15:1376-1383.
24. Vignjevic D., Schoumacher M., Gavert N., Janssen K.P., Jih G., Lae M., et al. A novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 2007, 67:6844-6853.
25. Onodera M., Zen Y., Harada K., Sato Y., Ikeda H., Itatsu K., et al. Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma. Lab Invest 2009, 89:1261-1274.
26. Hsiung C.A., Lan Q., Hong Y.C., Chen C.J., Hosgood H.D., Chang I.S., et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet 2010, 6.
27. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103-1109.
28. Pelosi G., Barisella M., Pasini F., Leon M.E., Veronesi G., Spaggiari L., et al. CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol 2004, 17:711-721.
29. Vogt A.P., Cohen C., Siddiqui M.T. Fascin as an identifier of metastatic urothelial carcinoma: a retrospective study of fine-needle aspiration cell blocks and histologic tissue microarrays. Diagn Cytopathol 2012, 40:882-886.
30. Al-Alwan M., Olabi S., Ghebeh H., Barhoush E., Tulbah A., Al-Tweigeri T., et al. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One 2011, 6:e27339.
31. Uyama N., Iimuro Y., Kawada N., Reynaert H., Suzumura K., Hirano T., et al. Fascin, a novel marker of human hepatic stellate cells, may regulate their proliferation, migration, and collagen gene expression through the FAK-PI3K-Akt pathway. Lab Invest 2012, 92:57-71.
32. Lin C.K., Su H.Y., Tsai W.C., Sheu L.F., Jin J.S. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters. Dis Markers 2008, 25:17-26.
33. Lu X.F., Li E.M., Du Z.P., Xie J.J., Guo Z.Y., Gao S.Y., et al. Specificity protein 1 regulates fascin expression in esophageal squamous cell carcinoma as the result of the epidermal growth factor/extracellular signal-regulated kinase signaling pathway activation. Cell Mol Life Sci 2010, 67:3313-3329.
34. Okada M., Nishio W., Sakamoto T., Uchino K., Yuki T., Nakagawa A., et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004, 78:216-221.
35. Liu L., Liu B., Zhu L.L., Zhang W., Li Y. Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer. Bioanalysis 2012, 4:2367-2374.
36. Molina R., Filella X., Auge J.M., Fuentes R., Bover I., Rifa J., et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small-cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003, 24:209-218.
37. Cedres S., Nunez I., Longo M., Martinez P., Checa E., Torrejon D., et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011, 12:172-179.